Acorda Therapeutics (ACOR) Rating Lowered to Sell at ValuEngine

Acorda Therapeutics (NASDAQ:ACOR) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

A number of other research analysts have also recently commented on the company. Goldman Sachs Group upgraded Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research note on Wednesday. Oppenheimer increased their price target on Acorda Therapeutics from $18.00 to $21.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target (down from $34.00) on shares of Acorda Therapeutics in a research note on Wednesday, January 17th. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, January 9th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.35.

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded up $0.20 on Friday, hitting $24.05. The stock had a trading volume of 561,803 shares, compared to its average volume of 830,589. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00. The company has a market cap of $1,130.00, a PE ratio of -19.88 and a beta of 1.63. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49.

In related news, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $27.58, for a total transaction of $854,980.00. Following the completion of the transaction, the insider now directly owns 5,275 shares of the company’s stock, valued at approximately $145,484.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the transaction, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Acorda Therapeutics by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock worth $84,871,000 after purchasing an additional 168,571 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Acorda Therapeutics by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock worth $62,813,000 after acquiring an additional 283,091 shares in the last quarter. State Street Corp raised its position in shares of Acorda Therapeutics by 52.4% in the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after acquiring an additional 851,290 shares in the last quarter. Northern Trust Corp raised its position in shares of Acorda Therapeutics by 65.2% in the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after acquiring an additional 354,304 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Acorda Therapeutics by 13.7% in the 3rd quarter. Macquarie Group Ltd. now owns 683,761 shares of the biopharmaceutical company’s stock worth $16,171,000 after acquiring an additional 82,642 shares in the last quarter.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/09/acorda-therapeutics-acor-rating-lowered-to-sell-at-valuengine.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply